Summary
This is the largest-known study of the abortion pill based on the analysis of data from an all-payer insurance claims database that includes 865,727 prescribed Mifepristone abortions from 2017 to 2023.
10.93 percent of women experience sepsis, infection, hemorrhaging, or another serious adverse event within 45 days following a Mifepristone abortion.
The real-world rate of serious adverse events following Mifepristone abortions is at least 22 times as high as the summary figure of “less than 0.5 percent” in clinical trials reported on the drug label.
Any other medication with that level of adverse events would have been pulled from the market once the adverse event rate reached 2%.
The abortion industry insists Mifepristone is safer than Tylenol.
That is a lie.
The abortion industry blames Georgia’s pro-life laws for the harm and death of women.
That is a lie.
Mifepristone abortions account for approximately 63% of abortions in the United States.
In Georgia, chemical abortions account for 83% of all abortions, a full 20 points higher than the national average.
Everyone in our state should be highly concerned.
Georgia Life Alliance is working with our nationwide coalition to require that the FDA:
Publicly and widely acknowledge that chemical abortion is extremely dangerous.
Re-institute the Risk Evaluation and Mitigation Strategies (REMS,) a program that FDA can require for medications with serious safety concerns.
Re-institute detailed reporting requirements.
Most importantly, to reconsider the approval of Mifepristone altogether.
GLA Committee continues its work with state legislators and the executive branch to educate them on this statewide issue and to protect women and girls from these dangerous drugs.
